JP2019508504A - 疾病の処置に有用なｃ−グリコシド化合物 - Google Patents

疾病の処置に有用なｃ−グリコシド化合物 Download PDF

Info

Publication number
JP2019508504A
JP2019508504A JP2018567029A JP2018567029A JP2019508504A JP 2019508504 A JP2019508504 A JP 2019508504A JP 2018567029 A JP2018567029 A JP 2018567029A JP 2018567029 A JP2018567029 A JP 2018567029A JP 2019508504 A JP2019508504 A JP 2019508504A
Authority
JP
Japan
Prior art keywords
methyl
pyran
tetrahydro
hydroxymethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018567029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508504A5 (enExample
Inventor
ダブリュー． ジャネトカ ジェイムス
ダブリュー． ジャネトカ ジェイムス
マイドック−マクグレーン ローレル
マイドック−マクグレーン ローレル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fimbrion Therapeutics Inc
Original Assignee
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fimbrion Therapeutics Inc filed Critical Fimbrion Therapeutics Inc
Publication of JP2019508504A publication Critical patent/JP2019508504A/ja
Publication of JP2019508504A5 publication Critical patent/JP2019508504A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018567029A 2016-03-11 2017-03-11 疾病の処置に有用なｃ−グリコシド化合物 Pending JP2019508504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307078P 2016-03-11 2016-03-11
US62/307,078 2016-03-11
PCT/US2017/021983 WO2017156508A1 (en) 2016-03-11 2017-03-11 C-glycoside compounds useful for treating disease

Publications (2)

Publication Number Publication Date
JP2019508504A true JP2019508504A (ja) 2019-03-28
JP2019508504A5 JP2019508504A5 (enExample) 2020-04-23

Family

ID=59789872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018567029A Pending JP2019508504A (ja) 2016-03-11 2017-03-11 疾病の処置に有用なｃ−グリコシド化合物

Country Status (5)

Country Link
US (1) US20200002303A1 (enExample)
EP (1) EP3426260A4 (enExample)
JP (1) JP2019508504A (enExample)
CN (1) CN108883122A (enExample)
WO (1) WO2017156508A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551973A (ja) * 2019-10-16 2022-12-14 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10738070B2 (en) 2016-03-23 2020-08-11 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of FimH useful for treating disease
EP3820856B9 (en) * 2018-07-10 2023-07-12 GlaxoSmithKline Intellectual Property Development Limited C-mannoside compopunds useful for the treatment of urinary tract infections
US12297223B2 (en) 2019-05-07 2025-05-13 Glaxosmithkline Intellectual Property Development Limited Compounds
US12351597B2 (en) 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
CN113582956A (zh) * 2020-04-30 2021-11-02 华东师范大学 含硫芳基碳苷类化合物及其合成方法和应用
CN115197185B (zh) * 2021-04-12 2024-03-22 中国科学院大连化学物理研究所 一种过渡金属催化的吡喃糖苷衍生物的制备方法
CN115656356B (zh) * 2022-09-30 2025-03-21 南京正济医药研究有限公司 4-羟基-7-苯氧基异喹啉-3-甲酸甲酯及其有关物质的测定方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109263A1 (en) * 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
WO2014165107A2 (en) * 2013-03-12 2014-10-09 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) * 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109263A1 (en) * 2011-02-07 2012-08-16 The Washington University Mannoside compounds and methods of use thereof
WO2014165107A2 (en) * 2013-03-12 2014-10-09 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
WO2014194270A1 (en) * 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551973A (ja) * 2019-10-16 2022-12-14 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
US12497383B2 (en) 2019-10-16 2025-12-16 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases

Also Published As

Publication number Publication date
WO2017156508A1 (en) 2017-09-14
EP3426260A1 (en) 2019-01-16
EP3426260A4 (en) 2019-08-14
US20200002303A1 (en) 2020-01-02
CN108883122A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
US20220235087A1 (en) Mannose-derived antagonists of fimh useful for treating disease
US20250009723A1 (en) Mannose-derived antagonists of fimh useful for treating disease
JP2019508504A (ja) 疾病の処置に有用なｃ−グリコシド化合物
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
CA2894536C (en) Mannose derivatives for treating bacterial infections
US10428057B2 (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
EP3027616B1 (en) Azaindole compounds as modulators of rorc
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
US11560366B2 (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
KR20190026827A (ko) 방향족 아세틸렌 또는 방향족 에틸렌계 화합물, 그의 중간체, 제조 방법, 약물 조성물 및 용도
EP3883925A1 (en) Cyclic ureas
EP3041821B1 (en) Bicylic compounds as modulators of rorgamma
EP3917926B1 (en) Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
AU2007267983B2 (en) Imidazoazepinone compounds
WO2014055474A1 (en) Mannose derivatives for treating bacterial infections
CA2905019A1 (en) Mannose derivatives for treating bacterial infections
JP2025532626A (ja) 複素環式ｓｉｋ阻害薬
US20190382396A1 (en) Salts of bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211012